None

Pending EC decision: Icandra (previously Vildagliptin/Metformin Hydrochloride Novartis), vildagliptin / metformin, Opinion date: 20-Sep-2012

Vildagliptin For Type II Diabetes Can Be Combined With All Other Diabetes Drugs

Partial changes to the efficacy and indication of Novartis Pharmaceuticals’ DPP-4 inhibitor drug Equa (vildagliptin) have been approved, the company announced on Feb. 28.

Human medicines European Public Assessment Report (EPAR): Icandra (previously Vildagliptin/Metformin Hydrochloride Novartis), vildagliptin / metformin, Revision: 7, Authorised

EU body backs Galvus, Eucreas for diabetes indications

ZURICH (Reuters) - European regulators on Friday issued positive opinions for new indications of Novartis AG drugs Galvus (vildagliptin) and Eucreas (vildagliptin plus metformin) in combination wi...

REFILE: EU body backs Galvus, Eucreas for diabetes indications

ZURICH (Reuters) - European regulators on Friday issued positive opinions for new indications of Novartis AG drugs Galvus (vildagliptin) and Eucreas (vildagliptin plus metformin) in combination wi...

Novartis Data at EASD From 45,000-Patient Study Demonstrate Real-World Effectiveness of Galvus in Patients With Type 2 Diabetes

• Data from global EDGE study show 1.19% reduction in HbA1c when vildagliptin was added to existing oral anti-diabetes therapies1 • A higher proportion of patients responded to vildagliptin...

Novartis announces two CHMP positive opinions for new indications of Galvus and Eucreas ...

Positive opinion for the use of vildagliptin, with or without metformin, in combination with a stable dose of insulin[1] Additional positive opinion for the use of vildagliptin in combination...

Novartis announces two CHMP positive opinions for new indications of Galvus® and Eucreas® combined with other diabetes treatments

Novartis International AG / Novartis announces two CHMP positive opinions for new indications of Galvus® and Eucreas® combined with other diabetes treatments . Processed and transmitted by Thomson...

Pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV inhibitor after oral administration in rats.

The pharmacokinetics of lipoyl vildagliptin, a novel dipeptidyl peptidase IV (DPP IV) inhibitor, was studied in rats after oral administration for developing it as an antidiabetic agent. A liquid chro...

The dipeptidyl peptidase IV (CD26, EC 3.4.14.5) inhibitor vildagliptin is a potent antihyperalgesic in rats by promoting endomorphin-2 generation in the spinal cord.

We have reported previously that the dipeptidyl peptidase IV inhibitor Ile-Pro-Ile had an antihyperalgesic action in rats when given intrathecally in the carrageenan-induced hyperalgesia, as detected...

Vildagliptin: a review of its use in type 2 diabetes mellitus.

Vildagliptin (Galvus®, Jalra®, Xiliarx®) is an orally administered dipeptidyl peptidase-4 (DPP-4) inhibitor. In patients with type 2 diabetes mellitus, vildagliptin 50 mg twice daily is indicated...

Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.

Objective: To assess the effects of meal timing on the pharmacokinetics and pharmacodynamics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin in Japanese patients with Type 2 diabetes. Me...

FC1 Dipeptidyl peptidase IV inhibitors limit myocardial infarct size in a glucose-sensitive manner.

Rationale The novel anti-diabetic agents, vildagliptin and sitagliptin, reduce blood glucose by augmenting endogenous levels of glucagon-like peptide (GLP-1), a substance which confers cardioprotectio...